Maze Therapeutics, Inc. (MAZE) stock intrinsic value fair value estimate & owner earnings analysis

Maze Therapeutics is a South San Francisco drug developer with no approved products. Its two wholly owned programs are MZE829, an oral pill that blocks the APOL1 protein in people with APOL1-mediated kidney disease, and MZE782, an oral SLC6A19 inhibitor being readied for Phase 2 trials in phenylketonuria (PKU) and chronic kidney disease. A third compound, MZE001 for Pompe disease, was licensed to Shionogi in 2024. In its Phase 2 proof-of-concept study MZE829 cut urine protein (uACR) by 35.6% on average at week 12 in 12 evaluable patients, and by 48.6% in patients without diabetes. The company plans to move it into a pivotal program. What the business earns today: the only money coming in is licensing income. In 2024 Maze booked $167.5 million, mostly Shionogi's $150 million upfront payment, and that made 2024 a one-off profitable year. In 2025 there was no revenue. Owner earnings (operating cash flow excluding working-capital swings, with stock compensation and capital spending counted as costs) were about -$127 million, or -$2.95 per share. The first half of 2026 included a $20 million Shionogi milestone, paid when Shionogi dosed the first Pompe patient in March 2026. Without it, the company is running at roughly -$47 million a quarter on the same basis: an operating loss of about $48 million in the second quarter, of which about $8 million was stock compensation. That is close to $190 million a year, about $155 million of it in cash. Two consecutive quarters confirm this rate, which is well above 2025 because clinical and manufacturing spending is rising. The 2024 year is excluded from the earnings level because it was a one-time license payment. Balance sheet (June 30, 2026): about $495 million of cash and marketable securities. This includes roughly $150 million of new equity raised in the first half of 2026 and a $40 million Hercules term loan taken in February 2026. The loan floats with the prime rate, has a 7.95% floor, is interest-only until 2030 and matures February 1, 2031, with an exit fee of up to 6.45%. Counting the exit fee and the extra cost of a rate above 6%, we treat it as about $46 million owed. Up to $160 million more can be borrowed if milestones are met. The loan requires Maze to keep cash of at least half the loan balance unless its market value clears set thresholds. With this much cash, that is not a constraint today. There are about 59 million shares, including pre-funded warrants. How we value it: we count only what can be pointed to in the filings. Neither drug has finished a pivotal trial, so no product sales and no royalties are credited in any case. Shionogi's remaining $255 million of milestones and its royalties (low double digits to twenty percent of sales) depend on trial results that have not happened yet. The question is how much of today's cash is left for shareholders after the development plan is paid for. Base case (-$0.89 per share): spending continues at the current rate of about $190 million a year, including stock compensation. The cash left after repaying the loan is used up by about mid-2029, which is roughly when pivotal data for MZE829 could come. No value is assigned to what that spending produces. The business is worth about -$7 million (the $495 million of cash less the present value of the planned spending). It owes about $46 million, so the result is about -$53 million. This does not mean debt swamps the company: the $40 million loan is small next to its cash. The negative figure comes from counting stock compensation as a real cost (it dilutes owners) on top of spending all the cash. Bear case (-$1.05): spending rises as MZE829 enters a pivotal trial, to about $175 million of cash in the first year and $205 million in the second, so the cash runs out sooner. The programs produce nothing sellable, and remaining lease and shutdown costs of about $10 million must be paid. Business about -$16 million, debt $46 million, equity about -$62 million. Bull case (+$1.81): Maze repeats what it did with MZE001. On the strength of the Phase 2 data it licenses or co-develops MZE829 by mid-2027 for about $150 million upfront, the same size as the Shionogi deal, and the partner carries the pivotal costs. Shionogi's Pompe program also advances and pays one more development milestone of about $20 million in 2028, the same size as the one already paid. Business about $61 million, debt $46 million, equity about +$107 million. The main way this could be wrong: MZE829 succeeds in a pivotal trial and reaches the market. APOL1 kidney disease has no approved treatment, so an approved MZE829 would be worth far more than any of these cases. That outcome is left out not because we think it will not happen, but because nothing in the record yet shows it will. A positive pivotal readout, an approval or a signed partnership would change this assessment. Until then, the shares are a claim on cash that the company intends to spend on clinical trials.